Panuveitis Treatment Market
Market Insights on Panuveitis Treatment covering sales outlook, demand forecast & up-to-date key trends
Panuveitis Treatment Market by Drug Class, Route of Administration, Distribution Channel & Region | Forecast 2023 to 2033
Panuveitis Treatment Market Snapshot (2023 to 2033)
The global panuveitis treatment market garnered a market value of US$ 3.76 Billion in 2022 and is expected to accumulate a market value of US$ 8.9 Billion by registering a CAGR of 9.5% in the forecast period 2023-2033. The growthof the Panuveitis treatment market can be attributed to growing prevalence of uveitis, increasing awareness about the condition, and a rise in the geriatric population worldwide. The market for Panuveitis treatment registered a CAGR of 4.7% in the historical period 2018 to 2022
Panuveitis is a serious inflammatory condition that affects the uveal tract of the eye, which includes the iris, ciliary body, and choroid. Treatment for panuveitis usually involves a combination of medications and sometimes surgery. The primary goal of treatment is to reduce inflammation and prevent further damage to the eye. Treatment typically begins with the use of corticosteroid eye drops or injections to reduce inflammation in the eye. In some cases, oral corticosteroids may also be used.
|
Report Attribute |
Details |
|
Expected Market Value (2023) |
US$ 3.76 billion |
|
Anticipated Forecast Value (2033) |
US$ 8.9 billion |
|
Projected Growth Rate (2023 to 2033) |
9.5% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
2018 to 2022 Panuveitis Treatment Market Demand Analysis vs. Forecast 2023 to 2033
According to market research and competitive intelligence provider Future Market Insights- the market for Panuveitis treatment reflected a value CAGR of 4.7% during the historical period, 2018 to 2022.
The panuveitis treatment market is expected to have experienced moderate growth during this period, driven by an increasing prevalence of uveitis and a rise in the geriatric population worldwide. Advances in technology and the introduction of new therapies may have also contributed to market growth.
The market for panuveitis treatment is expected to grow in the coming years, driven by an increasing number of clinical trials for new treatments and the introduction of advanced therapies. Thus, the market for Panuveitis treatment is expected to register a CAGR of 9.5% in the forecast period 2023 to 2033.
Which are Some Prominent Drivers of Panuveitis Treatment Market?
Increasing prevalence of uveitis and aging population shaping landscape for panuveitis market
The rising prevalence of uveitis, a condition that is often associated with panuveitis, is a significant driver of the market. According to the World Health Organization, uveitis is one of the leading causes of blindness worldwide.
Advances in medical technology have led to the development of new treatments and therapies for panuveitis, which has expanded the market for panuveitis treatments. The global population is aging, which has led to a higher incidence of age-related eye diseases, including uveitis and panuveitis. This demographic trend is expected to continue to drive demand for panuveitis treatments.
As awareness of uveitis and other eye diseases grows, patients and healthcare providers are more likely to seek out and recommend treatments for panuveitis. As healthcare expenditure continues to rise worldwide, patients are more likely to seek out and receive treatments for panuveitis, which is likely to further drive market growth.
As emerging economies continue to grow and develop, the market for panuveitis treatments is expected to expand, driven by rising incomes and greater access to healthcare services.
Availability of treatments driving the growth of panuveitis treatments market
Corticosteroid eye drops or injections: Corticosteroids are commonly used to reduce inflammation in the eye. They may be administered as eye drops, injections or pills.
Immunosuppressive drugs: These drugs suppress the immune system and reduce inflammation. They may be used in combination with corticosteroids or as a standalone treatment.
Biologic agents: Biologic agents are a new class of medications that target specific molecules involved in inflammation. These drugs are used in patients who do not respond to other treatments.
Surgery: In some cases, surgery may be necessary to remove scar tissue or repair damage to the eye. Procedures such as vitrectomy, which involves removing the vitreous gel from the eye, may be performed to improve vision in patients with severe panuveitis.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhat are the Challenges Faced by the Panuveitis Treatment Market?
Limited availability of effective treatments along with regulatory challenges derailing market growth
While there are several treatments available for panuveitis, there is no cure for the condition. In addition, some patients may not respond to existing treatments, leading to the need for new and more effective therapies. The cost of treatment for panuveitis can be high, particularly for biologic agents and other advanced therapies. This can limit access to treatment for some patients.
The approval process for new treatments can be lengthy and costly, which can delay the introduction of new therapies to the market. Many patients and healthcare providers may not be familiar with panuveitis and its treatment options, which can delay diagnosis and treatment.
Developing new treatments for panuveitis can be challenging due to the complexity of the condition and the need for large, well-designed clinical trials to demonstrate safety and efficacy. Thus, the aforementioned factors are hampering the market growth of panuveitis treatment market.
Region-Wise Insights
Rising Awareness About Eye Diseases Creating Lucrative Opportunities for Panuveities Treatment Market in North America?
Adoption of advanced therapies contributing to growth of panuveitis treatment market
The North America panuveitis treatment market is a significant contributor to the global market, accounting for a significant share of the overall market. The United States and Canada are the major markets in North America, and factors such as the presence of advanced healthcare infrastructure, high healthcare expenditure, and increasing prevalence of eye diseases are driving the growth of the market.
In addition, the rising awareness about eye diseases and increasing adoption of advanced therapies are also contributing to the growth of the North America panuveitis treatment market. The availability of advanced therapies such as biologic agents, corticosteroids, and immunosuppressive drugs, coupled with the presence of a large patient population, is expected to drive the demand for panuveitis treatment in the region.
The North America panuveitis treatment market is expected to continue to grow in the coming years, driven by increasing investment in research and development, the introduction of new treatments, and increasing awareness about the condition and its treatment options. Thus, North America is expected to possess a 45% market share for the panuveitis treatment market in 2023.
Advanced Healthcare Infrastructure Bolstering Market Growth for Panuveities Treatment in Europe?
Availability of advanced therapies propelling market growth of panuveities treatment market
There is an increasing prevalence of eye diseases in Europe, including panuveitis. This is driving the demand for panuveitis treatment in the region. Europe has a highly advanced healthcare infrastructure, which includes advanced ophthalmic facilities, highly skilled healthcare professionals, and advanced medical technologies. This infrastructure is driving the growth of the panuveitis treatment market in Europe.
Europe has a robust research and development sector and a favorable regulatory environment, which has led to the availability of several advanced therapies for panuveitis treatment. These therapies include corticosteroids, immunosuppressive drugs, and biologic agents. There is an increasing awareness about eye diseases in Europe, which is leading to earlier diagnosis and treatment of these conditions, including panuveitis.
The geriatric population in Europe is growing, and this population is at an increased risk of developing eye diseases such as panuveitis. This is driving the demand for panuveitis treatment in the region. Thus, Europe is expected to possess a 36% market share for panuveitis treatment market in 2023.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Category-Wise Insights
Availability of Specialized Treatments in Hospital Pharmacies Favoring Growth of Panuveitis Treatment Market?
Collaboration with Healthcare Professionals driving growth of Hospital Pharmacies
Hospital pharmacies often stock specialized medications and therapies that may be required for the treatment of panuveitis. This includes biologic agents, immunosuppressive drugs, and corticosteroids, which may not be available in other types of pharmacies.
Hospital pharmacies typically work closely with healthcare professionals such as ophthalmologists and rheumatologists, who are involved in the diagnosis and treatment of panuveitis. This collaboration can help ensure that patients receive appropriate and effective treatments.
Hospital pharmacies often have pharmacists and other healthcare professionals with specialized training and expertise in the treatment of complex conditions such as panuveitis. This expertise can help ensure that patients receive the best possible care.
Hospital pharmacies are subject to stringent regulatory requirements, which can help ensure the quality and safety of medications and therapies used for the treatment of panuveitis. Hospital pharmacies often provide additional supportive services to patients, such as patient education, medication management, and medication delivery services, which can help improve patient outcomes. Thus, hospital pharmacies are expected to possess a 49% market share for panuveitis treatment market in 2023.
Market Competition
Key players in the Panuveitis treatment Market are Allergan, Inc., Novartis AG, Bausch Health Inc., AbbVie Inc., Tarsier Pharma, EyeGate Pharmaceuticals, Inc., Alimera Science Inc., Eyepoint Pharmaceutical, Santen Pharmaceutical
- Bausch Health Inc. has developed a drug called Uvadex (methoxsalen) for the treatment of certain forms of uveitis, including panuveitis. Uvadex is an oral medication that works by sensitizing the immune cells that cause inflammation in the eye to a type of light called ultraviolet A (UVA).
- AbbVie Inc. has developed a drug called Humira (adalimumab) for the treatment of various autoimmune and inflammatory disorders, including certain forms of uveitis, including panuveitis. Humira is a monoclonal antibody that selectively binds to a pro-inflammatory protein called tumor necrosis factor alpha (TNF-α), which is involved in the development of inflammation.
Report Scope
|
Report Attribute |
Details |
|
Market Value in 2023 |
US$ 3.76 billion |
|
Market Value in 2033 |
US$ 8.90 billion |
|
Growth Rate |
CAGR of 9.5% from 2023 to 2033 |
|
Base Year for Estimation |
2022 |
|
Historical Data |
2018 to 2022 |
|
Forecast Period |
2023 to 2033 |
|
Quantitative Units |
Revenue in US$ billion and CAGR from 2023-2033 |
|
Report Coverage |
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
|
Segments Covered |
|
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
|
|
Customization |
Available Upon Request |
Key Segments Profiled in the Panuveitis Treatment Industry Survey
Drug Class:
- Anti-inflammatory
- Antimicrobial Drugs
- Immunotherapy & Targeted Therapies
Route of Administration:
- Oral
- Topical
Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa
Frequently Asked Questions
At what rate did the panuveitis treatment market flourish from 2018 to 2022?
From 2018 to 2022, the panuveitis treatment market grew at a CAGR of 4.7%
What will be the growth rate of the global panuveitis treatment market during the forecast period?
The global panuveitis treatment market is expected to grow with a 9.5% CAGR from 2023 to 2033.
What will be the projected market size of the panuveitis treatment market by 2033?
As of 2033, the panuveitis treatment market is expected to reach US$ 8.90 Billion
Which distribution channel segment is expected to dominate the global panuveitis treatment market during 2023?
Hospital pharmacies are expected to hold 49% of the market share in 2023 in the panuveitis treatment market.
How is the North America panuveitis treatment market projected to grow in 2023?
North America is expected to possess a 45% market share for Panuveitis treatment market in 2023.
How is the Europe panuveitis treatment market projected to grow in 2023?
Europe Panuveitis treatment market size is expected to possess 36% market share in 2023.
Table of Content
1. Executive Summary | Panuveitis Treatment Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033 5.3.1. Anti-inflammatory 5.3.2. Antimicrobial Drugs 5.3.3. Immunotherapy & Targeted Therapies 5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033 6.3.1. Oral 6.3.2. Topical 6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033 7.3.1. Hospital Pharmacies 7.3.2. Retail Pharmacies 7.3.3. Online Pharmacies 7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. South Asia 8.3.5. East Asia 8.3.6. Oceania 8.3.7. Middle East & Africa 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. United States. 9.2.1.2. Canada 9.2.2. By Drug Class 9.2.3. By Route of Administration 9.2.4. By Distribution Channel 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Drug Class 9.3.3. By Route of Administration 9.3.4. By Distribution Channel 9.4. Key Takeaways 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Drug Class 10.2.3. By Route of Administration 10.2.4. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Drug Class 10.3.3. By Route of Administration 10.3.4. By Distribution Channel 10.4. Key Takeaways 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. United Kingdom 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Europe 11.2.2. By Drug Class 11.2.3. By Route of Administration 11.2.4. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Drug Class 11.3.3. By Route of Administration 11.3.4. By Distribution Channel 11.4. Key Takeaways 12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. India 12.2.1.2. Malaysia 12.2.1.3. Singapore 12.2.1.4. Thailand 12.2.1.5. Rest of South Asia 12.2.2. By Drug Class 12.2.3. By Route of Administration 12.2.4. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Drug Class 12.3.3. By Route of Administration 12.3.4. By Distribution Channel 12.4. Key Takeaways 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. China 13.2.1.2. Japan 13.2.1.3. South Korea 13.2.2. By Drug Class 13.2.3. By Route of Administration 13.2.4. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Drug Class 13.3.3. By Route of Administration 13.3.4. By Distribution Channel 13.4. Key Takeaways 14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. Australia 14.2.1.2. New Zealand 14.2.2. By Drug Class 14.2.3. By Route of Administration 14.2.4. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Drug Class 14.3.3. By Route of Administration 14.3.4. By Distribution Channel 14.4. Key Takeaways 15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest of MEA 15.2.2. By Drug Class 15.2.3. By Route of Administration 15.2.4. By Distribution Channel 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Drug Class 15.3.3. By Route of Administration 15.3.4. By Distribution Channel 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. USA 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2022 16.1.2.1. By Drug Class 16.1.2.2. By Route of Administration 16.1.2.3. By Distribution Channel 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2022 16.2.2.1. By Drug Class 16.2.2.2. By Route of Administration 16.2.2.3. By Distribution Channel 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2022 16.3.2.1. By Drug Class 16.3.2.2. By Route of Administration 16.3.2.3. By Distribution Channel 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2022 16.4.2.1. By Drug Class 16.4.2.2. By Route of Administration 16.4.2.3. By Distribution Channel 16.5. Germany 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2022 16.5.2.1. By Drug Class 16.5.2.2. By Route of Administration 16.5.2.3. By Distribution Channel 16.6. United Kingdom 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2022 16.6.2.1. By Drug Class 16.6.2.2. By Route of Administration 16.6.2.3. By Distribution Channel 16.7. France 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2022 16.7.2.1. By Drug Class 16.7.2.2. By Route of Administration 16.7.2.3. By Distribution Channel 16.8. Spain 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2022 16.8.2.1. By Drug Class 16.8.2.2. By Route of Administration 16.8.2.3. By Distribution Channel 16.9. Italy 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2022 16.9.2.1. By Drug Class 16.9.2.2. By Route of Administration 16.9.2.3. By Distribution Channel 16.10. India 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2022 16.10.2.1. By Drug Class 16.10.2.2. By Route of Administration 16.10.2.3. By Distribution Channel 16.11. Malaysia 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2022 16.11.2.1. By Drug Class 16.11.2.2. By Route of Administration 16.11.2.3. By Distribution Channel 16.12. Singapore 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2022 16.12.2.1. By Drug Class 16.12.2.2. By Route of Administration 16.12.2.3. By Distribution Channel 16.13. Thailand 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2022 16.13.2.1. By Drug Class 16.13.2.2. By Route of Administration 16.13.2.3. By Distribution Channel 16.14. China 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2022 16.14.2.1. By Drug Class 16.14.2.2. By Route of Administration 16.14.2.3. By Distribution Channel 16.15. Japan 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2022 16.15.2.1. By Drug Class 16.15.2.2. By Route of Administration 16.15.2.3. By Distribution Channel 16.16. South Korea 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2022 16.16.2.1. By Drug Class 16.16.2.2. By Route of Administration 16.16.2.3. By Distribution Channel 16.17. Australia 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2022 16.17.2.1. By Drug Class 16.17.2.2. By Route of Administration 16.17.2.3. By Distribution Channel 16.18. New Zealand 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2022 16.18.2.1. By Drug Class 16.18.2.2. By Route of Administration 16.18.2.3. By Distribution Channel 16.19. GCC Countries 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2022 16.19.2.1. By Drug Class 16.19.2.2. By Route of Administration 16.19.2.3. By Distribution Channel 16.20. South Africa 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2022 16.20.2.1. By Drug Class 16.20.2.2. By Route of Administration 16.20.2.3. By Distribution Channel 16.21. Israel 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2022 16.21.2.1. By Drug Class 16.21.2.2. By Route of Administration 16.21.2.3. By Distribution Channel 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Drug Class 17.3.3. By Route of Administration 17.3.4. By Distribution Channel 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. Allergan, Inc. 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.2. Novartis AG 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.3. Bausch Health Inc. 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.4. AbbVie Inc. 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.5. Tarsier Pharma 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.6. EyeGate Pharmaceuticals, Inc. 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.7. Alimera Science Inc. 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.8. Eyepoint Pharmaceutical 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.9. Santen Pharmaceutical 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033 Table 2: Global Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 3: Global Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033 Table 4: Global Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 6: North America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 7: North America Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033 Table 8: North America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 10: Latin America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 11: Latin America Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033 Table 12: Latin America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 13: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 14: Europe Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 15: Europe Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033 Table 16: Europe Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 17: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 18: South Asia Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 19: South Asia Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033 Table 20: South Asia Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 21: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 22: East Asia Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 23: East Asia Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033 Table 24: East Asia Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 25: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 26: Oceania Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 27: Oceania Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033 Table 28: Oceania Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 29: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 30: MEA Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 31: MEA Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033 Table 32: MEA Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 2: Global Market Value (US$ Million) by Route of Administration, 2023 to 2033 Figure 3: Global Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033 Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033 Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033 Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033 Figure 8: Global Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 9: Global Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 10: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 11: Global Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033 Figure 12: Global Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 13: Global Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 14: Global Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 15: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 16: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 17: Global Market Attractiveness by Drug Class, 2023 to 2033 Figure 18: Global Market Attractiveness by Route of Administration, 2023 to 2033 Figure 19: Global Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 20: Global Market Attractiveness by Region, 2023 to 2033 Figure 21: North America Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 22: North America Market Value (US$ Million) by Route of Administration, 2023 to 2033 Figure 23: North America Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033 Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 28: North America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 29: North America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 30: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 31: North America Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033 Figure 32: North America Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 33: North America Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 34: North America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 35: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 36: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 37: North America Market Attractiveness by Drug Class, 2023 to 2033 Figure 38: North America Market Attractiveness by Route of Administration, 2023 to 2033 Figure 39: North America Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 40: North America Market Attractiveness by Country, 2023 to 2033 Figure 41: Latin America Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 42: Latin America Market Value (US$ Million) by Route of Administration, 2023 to 2033 Figure 43: Latin America Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033 Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 48: Latin America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 49: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 51: Latin America Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033 Figure 52: Latin America Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 54: Latin America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 55: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 57: Latin America Market Attractiveness by Drug Class, 2023 to 2033 Figure 58: Latin America Market Attractiveness by Route of Administration, 2023 to 2033 Figure 59: Latin America Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033 Figure 61: Europe Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 62: Europe Market Value (US$ Million) by Route of Administration, 2023 to 2033 Figure 63: Europe Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 64: Europe Market Value (US$ Million) by Country, 2023 to 2033 Figure 65: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 68: Europe Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 69: Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 70: Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 71: Europe Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033 Figure 72: Europe Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 73: Europe Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 74: Europe Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 75: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 76: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 77: Europe Market Attractiveness by Drug Class, 2023 to 2033 Figure 78: Europe Market Attractiveness by Route of Administration, 2023 to 2033 Figure 79: Europe Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 80: Europe Market Attractiveness by Country, 2023 to 2033 Figure 81: South Asia Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 82: South Asia Market Value (US$ Million) by Route of Administration, 2023 to 2033 Figure 83: South Asia Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 84: South Asia Market Value (US$ Million) by Country, 2023 to 2033 Figure 85: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 86: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 87: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 88: South Asia Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 89: South Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 90: South Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 91: South Asia Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033 Figure 92: South Asia Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 93: South Asia Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 94: South Asia Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 95: South Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 96: South Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 97: South Asia Market Attractiveness by Drug Class, 2023 to 2033 Figure 98: South Asia Market Attractiveness by Route of Administration, 2023 to 2033 Figure 99: South Asia Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 100: South Asia Market Attractiveness by Country, 2023 to 2033 Figure 101: East Asia Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 102: East Asia Market Value (US$ Million) by Route of Administration, 2023 to 2033 Figure 103: East Asia Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 104: East Asia Market Value (US$ Million) by Country, 2023 to 2033 Figure 105: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 106: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 107: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 108: East Asia Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 109: East Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 110: East Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 111: East Asia Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033 Figure 112: East Asia Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 113: East Asia Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 114: East Asia Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 115: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 116: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 117: East Asia Market Attractiveness by Drug Class, 2023 to 2033 Figure 118: East Asia Market Attractiveness by Route of Administration, 2023 to 2033 Figure 119: East Asia Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 120: East Asia Market Attractiveness by Country, 2023 to 2033 Figure 121: Oceania Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 122: Oceania Market Value (US$ Million) by Route of Administration, 2023 to 2033 Figure 123: Oceania Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 124: Oceania Market Value (US$ Million) by Country, 2023 to 2033 Figure 125: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 126: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 127: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 128: Oceania Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 129: Oceania Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 130: Oceania Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 131: Oceania Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033 Figure 132: Oceania Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 133: Oceania Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 134: Oceania Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 135: Oceania Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 136: Oceania Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 137: Oceania Market Attractiveness by Drug Class, 2023 to 2033 Figure 138: Oceania Market Attractiveness by Route of Administration, 2023 to 2033 Figure 139: Oceania Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 140: Oceania Market Attractiveness by Country, 2023 to 2033 Figure 141: MEA Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 142: MEA Market Value (US$ Million) by Route of Administration, 2023 to 2033 Figure 143: MEA Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 144: MEA Market Value (US$ Million) by Country, 2023 to 2033 Figure 145: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 146: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 147: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 148: MEA Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 149: MEA Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 150: MEA Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 151: MEA Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033 Figure 152: MEA Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 153: MEA Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 154: MEA Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 155: MEA Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 156: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 157: MEA Market Attractiveness by Drug Class, 2023 to 2033 Figure 158: MEA Market Attractiveness by Route of Administration, 2023 to 2033 Figure 159: MEA Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 160: MEA Market Attractiveness by Country, 2023 to 2033
Recommendations
Explore Healthcare Insights
View Reports
